Literature DB >> 8432817

Mammalian epithelial cell line kit for detection of Clostridium difficile toxin.

P Walpita1, G F Billman, H F Krous.   

Abstract

The performance characteristics of a mammalian epithelial (MEP) cell line kit (Cytotoxi Test; Advanced Clinical Diagnostics, Toledo, Ohio) for the detection of Clostridium difficile toxin was compared with that of conventional tissue culture assays with human embryonic lung (HEL) cells in shell vials and human foreskin fibroblasts (HFFs) in test tubes. One hundred forty-nine stool samples were tested. The MEP cells were at least as sensitive as the HEL cells for use in C. difficile toxin detection. Results for the MEP cells were also obtained considerably more rapidly than those for HEL cells when the cells were examined at 4 and 24 h and then every 24 h for up to 5 days. Approximately one-third of all positive MEP cells were detected at 4 h and 95% were detected by 48 h. In comparison, in the HEL shell vial monolayers, only 6% of the positive cells were detectable at 4 h and 76% were detectable at 48 h. The times for C. difficile toxin-induced cytotoxicity in HFF cells were similar to those in HEL cells. Shell vials carrying HEL cell monolayers (ViroMed Laboratories Inc., Minnetonka, Minn.) are a sensitive and reliable commercial source for the detection of C. difficile toxin, although they cannot detect C. difficile as rapidly as the Cytotoxi test with the MEP cell monolayers.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432817      PMCID: PMC262757          DOI: 10.1128/jcm.31.2.315-317.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Comparison of a dot immunobinding assay, latex agglutination, and cytotoxin assay for laboratory diagnosis of Clostridium difficile-associated diarrhea.

Authors:  G L Woods; P C Iwen
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 2.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

3.  Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro.

Authors:  A A Lima; D M Lyerly; T D Wilkins; D J Innes; R L Guerrant
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

4.  Treatment of antibiotic-associated Clostridium difficile diarrhea with oral vancomycin.

Authors:  D H Batts; D Martin; R Holmes; J Silva; F R Fekety
Journal:  J Pediatr       Date:  1980-07       Impact factor: 4.406

5.  Clostridium difficile-associated diarrhoea.

Authors:  R P Brettle; E Wallace
Journal:  J Infect       Date:  1984-03       Impact factor: 6.072

6.  Relative frequency of Clostridium difficile in patients with diarrheal disease.

Authors:  P H Gilligan; L R McCarthy; V M Genta
Journal:  J Clin Microbiol       Date:  1981-07       Impact factor: 5.948

7.  Development of a rapid enzyme immunoassay for Clostridium difficile toxin A and its use in the diagnosis of C. difficile-associated disease.

Authors:  J R DiPersio; F J Varga; D L Conwell; J A Kraft; K J Kozak; D H Willis
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

Review 8.  Antibiotic-associated pseudomembranous colitis.

Authors:  J G Bartlett
Journal:  Rev Infect Dis       Date:  1979 May-Jun

9.  Clostridium difficile and the aetiology of pseudomembranous colitis.

Authors:  H E Larson; A B Price; P Honour; S P Borriello
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

10.  Identification of toxigenic Clostridium difficile by the polymerase chain reaction.

Authors:  N Kato; C Y Ou; H Kato; S L Bartley; V K Brown; V R Dowell; K Ueno
Journal:  J Clin Microbiol       Date:  1991-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.